Tailored modulation of the inflammatory balance in COVID-19 patients admitted to the ICU?—a viewpoint

Critical Care

Marnix Kuindersma¹  Peter E. Spronk¹  Rocio Ramos Diaz² 

[1] Department of Intensive Care Medicine, Gelre Hospitals;Department of Medical Microbiology, Gelre Hospitals;

关键词: COVID-19;    Coronavirus;    Dexamethasone;    Inflammation;   

DOI  :  10.1186/s13054-021-03607-4

来源: DOAJ

【 摘 要 】

Abstract A growing consensus seems to be emerging that dexamethasone is a crucial component in the treatment of COVID-19-associated oxygen-dependent respiratory failure. Although dexamethasone has an undeniably beneficial effect on the inflammatory response in a subgroup of patients, the potential negative effects of corticosteroids must also be considered. In view of these negative effects, we argue that a one-size-fits-all dexamethasone approach may be potentially harmful in specific subsets of patients with COVID-19-associated ARDS. We propose a different individually tailored treatment strategy based on the patient’s inflammatory response.

【 授权许可】

Unknown